Emerging Trends in US Oncological Approvals: A 13-Year Review (1999-2011)

Drug Information Journal

Volumn 46, Issue 3, 2012, Pages 344-357

  Huang, Jing ^a   Zhang, Wenze ^b   Bowen, Debra ^c   Tam, Joemy ^d   Wu, Hsiaohui ^e   Fung, Man ^f  

^a CANCER HOSPITAL   (China)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Pharma Science Consulting   (United States)

^d PrimaNova BioSciences   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

approval; biomarkers; BLA; cancer drugs; companion diagnostic; FDA; NDA; targeted agents; trends

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ABARELIX; ABIRATERONE ACETATE; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; BENDAMUSTINE; BEVACIZUMAB; BIOLOGICAL MARKER; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CABAZITAXEL; CETUXIMAB; CLOFARABINE; CRIZOTINIB; DASATINIB; DEGARELIX; EPIRUBICIN; ERIBULIN; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IMATINIB; IPILIMUMAB; IXABEPILONE; LAPATINIB; LENALIDOMIDE; NELARABINE; NILOTINIB; OFATUMUMAB; OXALIPLATIN; PANITUMUMAB; PAZOPANIB; PEMETREXED; PRALATREXATE; ROMIDEPSIN; RUXOLITINIB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TRIPTORELIN; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ASTROCYTOMA; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHATIC LEUKEMIA; MESOTHELIOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE CARCINOMA; REVIEW; SOLID TUMOR; TREATMENT OUTCOME; UNITED STATES;

EID: 84864805649     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/0092861512441391     Document Type: Review

References (53)

1. Dar AC,Shokat KM.The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.Annu Rev Biochem. 2011;80:769-795.
2. Rodon J,Perez J,Kurzrock R.Combining targeted therapies: practical issues to consider at the bench and bedside.Oncologist. 2010;15 (1): 37-50.
3. Lorusso PM,Eder JP.Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology.Expert Opin Investig Drugs. 2008;17 (7): 1013-1028.
4. Gutierrez ME,Kummar S,Giaccone G.Next generation oncology drug development: opportunities and challenges.Nat Rev Clin Oncol. 2009;6 (5): 259-265.
5. Nair SR.Personalized medicine: striding from genes to medicines.Perspect Clin Res. 2010;1 (4): 146-150.
6. Pircher A,Hilbe W,Heidegger I,Drevs J,Tichelli A,Medinger M.Biomarkers in tumor angiogenesis and anti-angiogenic therapy.Int J Mol Sci. 2011;12 (10): 7077-7099.
7. Roberts PJ,Stinchcombe TE,Der CJ,Socinski MA.Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?.J Clin Oncol. 2010;28 (31): 4769-4777.
8. Ross JS.Cancer biomarkers, companion diagnostics and personalized oncology.Biomark Med. 2011;5 (3): 277-279.
9. Dimou A,Harrington K,Syrigos KN.From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer.Patholog Res Int. 2011;:312346.
10. Jing J,Greshock J,Holbrook JD, et al.Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.Mol Cancer Ther. 2012;11 (3): 720-729.
11. Tan DS,Thomas GV,Garrett MD, et al.Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.Cancer J. 2009;15 (5): 406-420.
12. Fine BM,Amler L.Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.Clin Pharmacol Ther. 2009;85 (5): 535-538.
13. Brannath W,Zuber E,Branson M, et al.Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.Stat Med. 2009;28 (10): 1445-1463.
14. Lee JJ,Gu X,Liu S.Bayesian adaptive randomization designs for targeted agent development.Clin Trials. 2010;7 (5): 584-596.
15. Berry DA.Adaptive clinical trials: the promise and the caution.J Clin Oncol. 2011;29 (6): 606-609.
16. Wang SJ,Hung HM,O'Neill RT.Adaptive patient enrichment designs in therapeutic trials.Biom J. 2009;51 (2): 358-374.
17. Korn EL,Freidlin B,Abrams JS,Halabi S.Design issues in randomized phase II/III trials. J Clin Oncol. 2012;30 (6): 667-671.
18. Renfro LA,Carlin BP,Sargent DJ.Bayesian adaptive trial design for a newly validated surrogate endpoint. Biometrics. 2012;68 (1): 258-267.
19. Pazdur R.The FDA's new oncology office.Clin Adv Hematol Oncol. 2005;3 (8): 612-613.
20. Faunce T,Townsend R,McEwan A.The Vioxx pharmaceutical scandal.J Law Med. 2010;18 (1): 38-49.
21. Scheen AJ.Suspension of the commercialization of sibutramine and rosiglitazone in Europe.Rev Med Liege. 2010;65 (10): 574-579.
22. Barden CJ,Weaver DF.The rise of micropharma.Drug Discov Today. 2010;15 (3-4): 84-87.
23. Hober S.Biotech reviews: keeping up with current developments.Biotechnol J. 2011;6 (9): 1031.
24. Biotech industry highlights.Biotechnol J. 2011;6 (12): 1433-1434.
25. Heinzelmann E.Biotech research: bringing better therapies to the people.Chimia (Aarau). 2010;64 (1-2): 91-93.
26. Azare J.From cancer alley to biotech: the importance of mentors.J Cancer Educ. 2009;24 (Suppl 2): S71-S72.
27. Ledford H.Monoclonal antibodies come of age.Nature. 2008;455 (7212): 437.
28. Food and Drug Administration. NME drug and new biologic approvals. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ucm121136.htm. Accessed January 2, 2012.
29. Food and Drug Administration. What's new from the Office of Oncology Drug Products. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm093885.htm. Accessed January 2, 2012.
30. Johnson JR,Ning YM,Farrell A,Justice R,Keegan P,Pazdur R.Accelerated approval of oncology products: the Food and Drug Administration experience.J Natl Cancer Inst. 2011;103 (8): 636-644.
31. Sridhara R,Johnson JR,Justice R,Keegan P,Chakravarty A,Pazdur R.Review of oncology and hematology drug product approvals at the US FDA between July 2005 and December 2007.J Natl Cancer Inst. 2010;102 (4): 230-243.
32. Center Watch. FDA approved drugs for oncology. Available at: http://www.centerwatch.com/drug-information/fda-approvals/drug-areas.aspx?AreaID=12. Accessed January 2, 2012.
33. The Pink Sheet Web site. http://thepinksheet.elsevierbi.com. Accessed January 2, 2012.
34. Food and Drug Administration. Class labeling changes to anti-EGFR monoclonal antibodies, cetuximab (Erbitux) and panitumumab (Vectibix): KRAS mutations. Available at: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm172905.htm. Accessed January 2, 2012.
35. Bokemeyer C,Bondarenko I,Makhson A, et al.Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.J Clin Oncol. 2009;27 (5): 663-671.
36. Van Cutsem E,Köhne CH,Hitre E, et al.Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.N Eng J Med. 2009;360 (14): 1408-1417.
37. Barton S,Starling N,Swanton C.Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies.Curr Cancer Drug Targets. 2010;10 (8): 799-812.
38. Clinical Trials. Cediranib maleate and cilengitide in treating patients with progressive or recurrent glioblastoma. Available at: http://clinicaltrials.gov/ct2/show/NCT00979862?term=cilengitide+biomarker&rank=1. Accessed January 2, 2012.
39. Clinical Trials. Temsirolimus plus neratinib for patients with metastatic HER2-amplified or triple negative breast cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01111825?term=HKI272&recr=Open&rank=3. Accessed January 2, 2012.
40. Clinical Trials. A study of GSK2118436 in BRAF mutant metastatic melanoma to the brain. Available at: http://clinicaltrials.gov/ct2/show/NCT01266967? term=GSK2118436+biomarker&rank=2. Accessed January 2, 2012.
41. Personalized Medicine Coalition. Policy. Available at: http://www.personalizedmedicinecoalition.org/policy. Accessed January 2, 2012.
42. Code of Federal Regulations. 2010, Title 21, Volume 5, Part 314. Applications for FDA approval to market a new drug, subpart D: FDA action on applications and abbreviated applications. Sec. 314.126: adequate and well-controlled studies (21CFR314.126). Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.126. Accessed January 2, 2012.
43. European Medicines Agency. ICH topic E9: statistical principles for clinical trials (1998). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002928.pdf. Accessed January 2, 2012.
44. Pazdur R.Endpoints for assessing drug activity in clinical trials.Oncologist. 2008;13 (Suppl 2): 19-21.
45. McKee AE,Farrell AT,Pazdur R,Woodcock J.The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.Oncologist. 2010;15 (Suppl 1): 13-18.
46. Chow SC,Chang M.Adaptive design methods in clinical trials: a review.Orphanet J Rare Dis. 2008;3:11.
47. Coffey CS,Kairalla JA.Adaptive clinical trials: progress and challenges.Drugs R D. 2008;9 (4): 229-242.
48. Food and Drug Administration. Guidance for industry: adaptive clinical trials design for drugs and biologics. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm201790.pdf. Accessed January 2, 2012.
49. Wang SJ,Bretz F.From adaptive design to modern protocol design for drug development, part I: editorial and summary of Adaptive Designs Session at the Third FDA/DIA Statistics Forum.Drug Info J. 2010;44:325-331.
50. HsuHSGuptaG.An overview of the FDA draft guidance on adaptive design clinical trials. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/../UCM209179.pdf. Accessed January 2, 2012.
51. WangSJ.The role of adaptive design in clinical development program. Available at: http://stat.rutgers.edu/iob/bioconf10/slides/SueJaneW.pdf. Accessed January 2, 2012.
52. Wiederrecht GJ,Hill RG,Beer MS.Partnership between small biotech and big pharma.IDrugs. 2006;9 (8): 560-564.
53. Moore K,Walker J.Deal-making trends in oncology.Nat Rev Drug Discov. 2009;8 (8): 604.